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excretion rates for all nucleosides in the same direction 
which was likely caused by a decrease in creatinine clear-
ance with age. There was a small evidence of sex-related 
differences for methylthioadenosine. The individual a pos-
teriori prediction of patient classification as area under 
the ROC with 5th and 95th percentile was 0.57(0.5–0.67) 
with sensitivity and specificity of 0.59(0.42–0.76) and 
0.57(0.45–0.7), respectively suggesting limited usefulness 
of 13 nucleosides/creatinine urine concentration measure-
ments in predicting disease in this population.
Conclusion Bayesian multilevel pharmacokinetics-driven 
modeling in metabolomics may be useful in understand-
ing the data and may constitute a new tool for searching 
towards potential candidates of disease indicators.
Keywords Multi-level modeling · Bayesian analysis · 
Pharmacokinetics · Metabolomics · Nucleosides · 
Methylthioadenosine · Cancer
1 Introduction
Multilevel (hierarchical) modeling, also known as random-
effects or mixed-effects modeling, is a generalization of 
regression methods known to outperform classical regres-
sion in predictive accuracy. This approach is becoming 
increasingly popular and the general motivation to use 
it lies in (i) adjusting estimates in case of repeated sam-
pling (e.g. in time-series cross-sectional data) (ii) adjust-
ing estimates in case of imbalance in sampling (e.g. when 
unbalanceness occurs in the data) (iii) modeling variation 
among individuals or groups in the data, (iiii) regulariza-
tion of parameter estimates with large number of predictors 
(McElreath 2014; Gelman and Feller 2015).
Abstract 
Introduction Multilevel modeling is a quantitative sta-
tistical method to investigate variability and relationships 
between variables of interest, taking into account popula-
tion structure and dependencies. It can be used for predic-
tion, data reduction and causal inference from experiments 
and observational studies allowing for more efficient eluci-
dation of knowledge.
Objectives In this study we introduced the concept of 
multilevel pharmacokinetics (PK)-driven modelling for 
large-sample, unbalanced and unadjusted metabolomics 
data comprising nucleoside and creatinine concentration 
measurements in urine of healthy and cancer patients.
Methods A Bayesian multilevel model was proposed to 
describe the nucleoside and creatinine concentration ratio 
considering age, sex and health status as covariates. The 
predictive performance of the proposed model was sum-
marized via area under the ROC, sensitivity and specificity 
using external validation.
Results Cancer was associated with an increase in meth-
ylthioadenosine/creatinine excretion rate by a factor of 1.42 
(1.09–2.03) which constituted the highest increase among 
all nucleosides. Age influenced nucleosides/creatinine 
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The concept of multilevel modeling constitutes a domain 
in pharmacokinetics (PK) for time-series data (Rodrigues 
et al. 2013) and has recently been established in the field of 
nutrikinetics (NK) (van Velzen et al. 2009).
Pharmacokinetics (PK) is a study of the time course 
of absorption, distribution, metabolism and excretion 
(ADME) of a drug and how these processes vary between 
individuals. In its general form, PK-based modeling pro-
vides mechanistic characterization of the observed concen-
tration–time profile of a drug in order to gain more insights 
towards understanding the phenomena associated with drug 
absorption and disposition (Liu et  al. 2013; Bonate et  al. 
2005). In PK, multilevel modeling is an often used tool to 
describe relationship between PK parameter and individual 
characteristics (e.g. age, sex, weight, smoking status, renal 
function) in terms of fixed effects (associated with covari-
ates) and random effects (unexplained variation between 
individuals) (Gelman et al. 1996; Imlach Gunasekara et al. 
2014). In principle, it shares similarities to metabolomics 
with the difference only related to the number of com-
pounds analyzed at a time.
Nutrikinetics (NK) in turn, is an application area of 
pharmacokinetics which studies the ADME of food com-
pounds or dietary supplements in the human organism 
including the interaction within the host metabolome and 
the gut microbiome (van Velzen et al. 2008). In NK, multi-
level partial least squared discriminant analysis (PLS-DA) 
models are used to account for between-subject variability 
and intra-individual variability (IIV) in order to develop 
classification models for longitudinal studies (Westerhuis 
et al. 2010).
Compared to NK, the aim of multilevel PK-driven mod-
eling does not lie in classification, but is mainly focused on 
modeling the concentration in a function of many different-
type covariates (numerical, categorical, binary). Such an 
approach allows for characterization of biological or physi-
ological phenomena in the system observed for each indi-
vidual simultaneously accounting for variability (Lavielle 
2014). From PK viewpoint, excretion into urine is one of 
the route of elimination of drugs and low molecular weight 
metabolites, and its rate can be predicted from creatinine 
clearance. From PK viewpoint, endogenous creatinine 
clearance or its indirect estimation is generally used to 
establish drug dosage for urinary excreted drugs. In metab-
olomics, creatinine is an indicator of urine dilution widely 
used for the purpose of normalization of metabolites deter-
mined in urine (Lindon et al. 2007).
Creatinine clearance can be estimated via the Cockcroft-
Gault formula from age, sex, weight and serum creatinine 
or from the Modification of Diet in Renal Disease Study 
(MDRD) which considers age, sex and serum creatinine. 
Therefore, we can expect that any differences in terms of 
age, sex or weight between individuals affect the production 
rate of creatinine between individuals (Levey et  al. 1999; 
Cockcroft et al. 1976). This phenomenon has a large impact 
in metabolomics observational studies for those metabo-
lites that are determined in urine as their concentration is 
usually normalized by creatinine clearance. In such a case, 
using traditional multivariate methods, e.g. PLS-DA, to 
discriminate between groups investigated, might lead to 
improper conclusions as any imbalance in age or sex will 
lead to biased inference of group difference.
Multilevel modeling has been used in unbalanced study 
design involving longitudinal studies covering individuals 
characterized by a wide age range (Morrell et  al. 2009). 
However, the applicability of multilevel modeling can also 
be extended to cross-sectional studies (at one specific time 
point) within nested and non-nested scenario (Gelman et al. 
2007; Gelman 2006). In this context, the idea of multilevel 
modeling fits into metabolomics studies which often suf-
fer from small data sets, high uncertainty and biological 
variability, making data modeling difficult (Bernillon et al. 
2000). So far, in the field of metabolomics little attention 
has been paid to develop or propose a modeling strategy 
that would account for the problem related to variability or 
uncertainty.
In this work we introduce the concept of multilevel 
PK-driven modeling within the Bayesian framework as a 
method to cope with large-sample, unbalanced, sex and age-
unadjusted data. In this study, metabolomics data involv-
ing measurement of 13 nucleosides in urine of healthy and 
urogenital track cancer patients with corresponding age 
and sex, were considered. Multilevel PK-driven regression 
model within Bayesian framework was used by assum-
ing probability distribution for all model parameters. The 
model developed assumed normally-distributed regulariz-
ing prior for case/control effect and informative priors form 
the MDRD formula imposed on age and sex. Accordingly, 
the model proposed was characterized via relationships 
between patient characteristics (age, sex, case/control sta-
tus) and model parameters. Accordingly, we evaluated the 
posterior probability of cancer occurrence in an individual 
person along with providing the classification performance 
of the model via area under the ROC, sensitivity and speci-
ficity. At the end we discuss the pros and cons of traditional 
hypothesis testing strategy versus multilevel PK-driven 
modeling in the context of metabolomics.
2  Methods
2.1  Data set used in the study
The data set used in this study consisted of n = 248 indi-
viduals (153 patients and 95 healthy individuals) and p = 13 
nucleosides concentrations determined using RP-HPLC 
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with UV–Vis spectrophotometric detection previously pub-
lished by Waszczuk-Jankowska et  al. (2012) in terms of 
the utility of different stationary phases for the determina-
tion of 13 nucleosides as potential cancer biomarkers. In 
the above-mentioned paper, concentrations of 13 metabo-
lites normalized by creatinine clearance were compared 
between healthy and urogenital tract cancer patients using 
Mann–Whitney U test statistics for all study participants. 
Significant differences were observed in 10 out of 13 nucle-
osides. More detailed description of the study participants, 
experimental conditions (LC instrumentation and chroma-
tographic conditions, stationary phases selection) and urine 
sample collection procedure, can be found therein.
In the present study, the same data set of 13 nucleosides’ 
concentrations with additional covariates such as age and 
sex were considered and subjected to multilevel PK-driven 
data analysis.
2.2  Model development
Dataset used in this study consisted of standardized and 
mean-centered n×p matrix (Y) representing the natural 
logarithm of nucleosides to creatinine concentration ratios. 
The dataset Y was randomly divided into training (70%) 
and validation (30%) set, Y =  (Ytrain,  Yval). Age, sex, and 
health status constituted the available covariates, where 
X = (Xtrain,  Xval) denotes the n×2 matrix covariate with age 
and sex as column vectors and Z = (Ztest,  Zval) denotes n×1 
vector describing health status (cancer versus healthy). The 
Zval values were further treated as missing to assess the pre-
dictive performance of the model in identifying disease sta-
tus of an individual subject.
Assuming steady-state conditions, the measured urine 
concentrations of nucleoside h (h = 1…p) in individual i 
(i = 1...n) expressed as mih is given by:
Similarly, measured concentration of creatinine in indi-
vidual i (ci) is given by:
where km,ih is the excretion rate (the product of clearance 
and unbound plasma concentration) of nucleoside h and 
kc,i is the excretion rate of creatinine in individual i; V0,i is 
the individual rate of diuresis (assumed to be equal for all 
metabolites and creatinine in individual i). The model was 
parameterized in terms of the natural log of the parameter 
values [e.g. ln(km,zi)] to simulate the usual lognormal distri-









and 휀c,i represent an additive (on a log scale) random error 
for concentration measurements. It was assumed that ε is 
normally distributed with mean 0 and variance–covariance 
denoted by Σm and variance 휎2c for nucleosides and creati-
nine, respectively.
The normalization of nucleosides concentration data by 
creatinine leads to diuresis-independent relationship:
Inter-individual variability (IIV) for all underlying 
parameter (km and kc) is further assumed to follow a log-
normal distribution:
where 훽km,h and 훽kc is the typical value of this parameter in 
the population, whereas 휂km,ih and 휂kc,i are random effects 




Combining both equations yields:
It can be compactly expressed as:
where 훽h is a population mean of the logarithm of the 
ratio of nucleosides to creatinine excretion rates and 휅ih is 
a random variable with mean 0 and variance–covariance 
denoted by Λ. As shown in Eq. (6), Λ can be decomposed 
into between-subject variabilities in nucleosides and creati-
nine excretion rates and their respective residual error vari-
abilities. Equations  (6) and (7) underlie which aspects of 
physiology could affect the measured nucleosides to creati-
nine excretion rates i.e. it depends on the excretion rate of a 
particular nucleoside and creatinine, whereas residuals are 
dependent on the measurement error and inter-individual 
variability of both nucleosides and creatinine.
2.3  Covariates
The potential effect of available covariates (age, sex and 
case/control status) on nucleoside/creatinine excretion rate 
was assessed in this study. Since creatinine excretion rate 
is among others age and sex-dependent, similar effect was 
assumed for nucleosides. Therefore, the following linear 







+ 휀m,ih − 휀c,i
(4)ln km,ih = ln 훽km,h + 휂km,ih







+ 휀m,ih − 휀c,i + 휂m,ih − 휂c,i
(7)yih = 훽h + 휅ih
(8)
yih = 훽0,h + 훽age,h ln(xi1∕50) + 훽sex,hxi2 + 훽cancer,hzi + 휅ih
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where 훽0,h is a population mean of the logarithm of the ratio 
of nucleosides to creatinine excretion rates for a 50  year-
old, healthy man. The 훽age,h is the effect of age, 훽sex,h is the 
effect of sex, and 훽cancer,k characterizes the effect of cancer 
presence on standardized, mean-centered log ratio of excre-
tion rates of nucleosides and creatinine. It should be noted 
that based on this data, without additional prior informa-
tion it is impossible to elucidate whether a given covariate 
affects creatinine or nucleosides excretion rate.
2.4  Priors
Following the JAGS parameterization (uncertainty is 
described as a precision, which is an inverse of variance), the 
stochastic part of the model can be represented as:
where MNV is multivariate normal distribution with a vec-
tor of expected logarithms of ratios of nucleoside/creati-
nine production rates.
In the model proposed we considered priors for the param-
eters related to covariates: (i) normally-distributed regu-
larizing prior with mean 0 and standard deviation from the 
uniform distribution imposed on case/control effect (10), (ii) 
normally-distributed informative prior with mean 0.203 and 
uniformly-distributed standard deviation for age (11), and 
normally-distributed informative prior with mean 0.293 and 
uniformly-distributed standard deviation for sex (12). The 
informative priors were elucidated from the MDRD formula 
(Cockcroft et al. 1976).
The intercept consisted of the vector of hyperprior popu-
lation mean parameters equal to zero and precision equal to 
0.0001 (13). Between/inter-individual subject variability fol-
lowed Wishart distribution with covariance Λ0 = 0.05 I13 (I 
– identity matrix) and degrees of freedom (ρ= 13) (14): 
where: 
(9)
yih ∼ MVN(훽0,h + 훽age,h ln(xi1∕50) + 훽sex,hxi2 + 훽cancer,hzi,Λ
−1)
(10)훽cancer,h ∼ N(0, 1/휎2cancer) for nucleosides h = 1...p
(11)훽age,h ∼ N(0.203, 1/휎2age) for nucleosides h = 1...p
(12)훽sex,h ∼ N(0.293, 1/휎2sex) for nucleosides h = 1...p
(13)훽0,h ∼ N(0, 0.0001) for nucleosides h = 1...p
휎cancer, 휎age, 휎sex ∼ dunif (0.001, 1000)
(14)Λ−1̃Wishart(𝜌Λ0,𝜌)
2.5  Inference about model parameters
The full joint probability of all parameters was obtained 
using Bayesian framework. The a posteriori distribution 
(up to the proportionality constant) of parameters 휃 is
where 휃 = (훽,Λ) is a set of all unknown model parameters 
as defined above, Y denotes a set of mean-centered and 
standardized log nucleoside/creatinine ratio measurements. 
The conditional distribution of 휃 given data (i.e.p(휃|Y)) 
denotes the posterior distribution. The p(Y|휃) is the distri-
bution of Y, which is a likelihood function when viewed as 
a function of model parameters, assuming that 휃 is known, 
The p(휃) is the distribution of 휃 without any knowledge on 
data, referred to as a prior distribution. Equation (15) dem-
onstrates that the posterior distribution of 휃 is proportional 
to the product of the likelihood of 휃 given Y and the prior 
distribution of 휃.
Similarly a posteriori predictions can be obtained:
where Ŷ  are nucleoside/creatinine ratios predictions.
2.6  Bayesian inferences for cancer development 
in individual subject
The practical usefulness of metabolomics measurements 
lies in the inference about the health status of the patients, 
i.e. elucidation of the probability of cancer presence given 
a set of nucleosides and creatinine measurements in urine. 
This problem can be viewed as an inference on the model 
parameters with missing covariates and can be written as:
Here the likelihood of Y and Z are treated as independ-
ent. 휃Z denotes a set of parameters for the model of cancer 
status. The p(Ztest, Zval|휃Z) was obtained assuming:
where pi denotes the individual probability of having can-
cer (thus 휃Z = pi) estimated from the data assuming diffuse 
beta prior:
The pi value corresponds to the individual probability of 
having cancer and in this work does not reflect the disease 
prevalence in the population. However, instead of Eq. (19), 
one can propose prior probability which is more informa-
tive, i.e. reflects disease prevalence and influence of differ-
ent covariates on the probability of cancer occurrence.
(15)p(휃|Y) ∝ p(Y|휃)p(휃)
(16)p(Ŷ|Y) = ∫ p(Ŷ|𝜃)p(𝜃|Y)d𝜃
(17)
p(휃, 휃Z, Zval|Y , Ztest) ∝ p(Y|Ztest, Zval, 휃)p(Ztest, Zval|휃Z)p(휃)p(휃Z)
(18)zĩdbern(pi)
(19)pĩdbeta(1, 1)
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2.7  Assessment via posterior predictive check and area 
under the ROC
Model performance was assessed by means of a posteriori 
predictive check. In this study, 5th, 50th and 95th percentile 
were used to summarize the data and model predictions. 
This graph enables the comparison between confidence 
intervals obtained from prediction and the observed data. 
When the corresponding percentile from the observed data 
falls outside the 90% confidence interval derived from pre-
dictions, there is an evidence of model misspecification.
The obtained posterior distribution of model parameters 
allowed for straightforward determination of patients clas-
sification performance as healthy or cancer (with uncer-
tainty) by means of the area under the ROC curve, sensitiv-
ity and specificity. We used colAUC function from caTools 
package to test the classification performance of a classifier 
separately for training and validation set.
2.8  Technical
The model was developed using JAGS 4.0.0. with rjags 
(Plummer 2015; Plummer et al. 2006), runjags (Denwood 
2016) and coda (Plummer et al. 2015) packages in R envi-
ronment (R Core Team 2015). Three MCMC chains of 
6000 iterations were simulated. The first 3000 iterations 
of each chain were discarded and every third sample was 
retained. Thus 3000 MCMC samples were used for subse-
quent analyses. Model convergence was assessed by Gel-
man-Rubin diagnostics available in JAGS. The MCMC 
chains were assumed to have reached the stationary distri-
bution if Gelman-Rubin values were less than 1.2 for all 
parameters. Furthermore, the trace history of MCMC sam-
ples for all chains were examined visually for all param-
eters, for which ‘fuzzy caterpillar’ suggests that MCMC 
chains had reached a stationary distribution. All the codes 
are available in the Supplementary Materials.
3  Results and discussion
3.1  Study design and model assumption
The present study constitutes an extension of the work con-
ducted by Waszczuk-Jankowska et al. (2012). In this study, 
the whole population of 248 individuals (153 patients and 
95 healthy individuals) was randomly divided into training 
(70%) (n = 178) and validation set (30%) (70 individuals). 
Detail characterization of both sets can be found in Table 1. 
Both datasets were unbalanced and mismatched in terms of 
age and sex and therefore, the population used in this study 
reflected common problems of study design related to mis-
match and unbalanceness. In terms of mismatch, such study 
design hinders the interpretation of results especially when 
applying a common Frequentist-based approach related to 
Mann–Whitney U test statistics and correction for multi-
plicity (false discovery rate (FDR), Bonferroni correction). 
Unbalanceness, in turn, affects the results provided by 
any classification method leading to biased results toward 
majority class and poor predictive performance of a classi-
fier (Chawla 2005).
In this work we developed a Bayesian multilevel PK-
driven model with prior information on age and sex elicited 
from the MDRD formula which estimates glomerular filtra-
tion rate based on creatinine and patient characteristics. For 
the case/control effect, we assumed a normally-distributed 
regularizing prior in order to provide a trade-off between 
overfitting and underfitting of the model. The concept of 
regularization is especially important when large number 
of predictors are introduced into the model or when we 
expect similar effects between variables (McElreath 2014).
3.2  Development and diagnostic of the regression 
model
Regression model with standardized, mean-centered nucle-
osides/creatinine excretion rates on a log scale as dependent 
variable was developed in a function of case/control effect, 
age and sex to assess the influence of cancer controlling for 
difference in age and sex among patients.
Diagnostic of the regression model was performed 
via checking model residuals and posterior predictive 
check. No observable pattern in the plot of residuals was 
Table 1  Detail characteristics 
of training and validation set 
with a set of corresponding 
covariates (age, sex, case/
control status)
Training set (n = 178) Validation set (n = 70)
Patients (n = 109) Healthy (n = 69) Patients (n = 44) Healthy (n = 26)
Age 64.04 (±11.89) 37.2 (±15.36) 66.22 (±10.42) 43.69 (±17.08)
Sex
Male 80 (73.4%) 24 (34.8%) 32 (72.7%) 11 (42.3%)
Female 29 (26.6%) 45 (65.2%) 12 (27.3%) 15 (57.7%)
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reported (no indication of non-constant error variance) 
therefore no violation from normality assumption can 
be expected (Fig. 1). We can therefore conclude, that the 
models of nucleosides/creatinine excretion rates are well 
fitted in a function of age, sex and case/control effect and 
thus, no over or under prediction of actual concentration 
is observed.
Posterior predictive check compares the actual data to 
the posterior predictions allowing for making inference 
whether a posteriori predictions from the model are con-
sistent with actual data. Confidence intervals obtained from 
a posteriori predictions and observations were compared 
as presented in Fig.  2. No systematic differences were 
observed, therefore we concluded good specification of the 
model developed on the training set.
Fig. 1  Model residuals in a function of age. Blue line represents 
the regression line, blue and red dots represent healthy and cancer 
patients, respectively. Pseu-pseudouridine; 1mA-1methyadenosine, 
3mC-3methylcytidine; X-xanthosine; A-adenosine; N4ac-N4acethyl-
cytidine; N2N2-N2N2dimethylguanosine; MTA-methythioadenosine; 
7mG-7methyladenosine; I-inosine; G-guanosine, 5mU-5methyluri-
dine; 6mA-6methyladenosine
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In Fig.  3, we present the typical nucleosides/creatinine 
excretion rates effect on the case/control status age and 
sex. As previously observed, as a consequence of cancer, 
normalized methylthioadenosine (MTA) concentration 
increased by a factor of 1.42 (1.09–2.03) whereas inosine 
(I) increased by 1.25 (1.04–1.6) on average, as evidenced 
by 5th and 95th percentile (assuming the model and the 
available data). For other nucleosides the mean effect is 
close to 1 (no effect). Age influences nucleosides/creatinine 
excretion rates for all nucleosides in the same direction, 
which is likely caused by a decrease in creatinine clearance 
with age as can be observed from the MDRD formula (Imai 
et al. 2007):
where kc denotes creatinine excretion rate, GFR is a 
glomerular filtration rate and Ccr indicates plasma cre-
atinine concentration. This equation shows that increase 
in nucleoside/creatinine excretion ratio by a factor of 
exp(0.203) = 1.22 should generally be expected due to 
(20)kc = GFR ⋅ CCr ≈ 186 ⋅ Age−0.203 ⋅ [0.742 if Female]
Fig. 2  Posterior predictive checks comparing the measured and predicted nucleosides/creatinine concentration ratios. The plot demonstrates 5th 
(red), 50th (black) and 95th (blue) percentiles for actual (solid lines) and posterior data (dotted lines). Actual data are presented on histograms
 E. Daghir-Wojtkowiak et al.
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dependence of creatinine excretion rate on age. Thus our 
measurements provide an evidence for age-dependent 
excretion rate for nucleosides as posterior probabilities for 
age effects (Fig. 3).
The effect of sex is different for different nucleosides/
creatinine excretion rates. The value of nucleosides/cre-
atinine excretion rates for pseu, 1 mA, 3mC, X, A, N4Ac, 
N2N2, 7mG, I, G, 5mU, 6  mA is generally higher for 
women in comparison to men. However this increase can 
be well explained by the effect of sex on creatinine clear-
ance (Eq.  20) as one can expect an increase by a factor 
of 1.35 (1/0.742) due to sex-dependent excretion rate of 
creatinine. The value of nucleosides/creatinine excretion 
Fig. 3  The a posteriori distribution of mean ratio of excretion rates 
of nucleosides to creatinine and the case/control status, age and sex 
effects on these parameters for each nucleoside tested. The distri-
bution was summarized as a boxplot with 5th, 25th, 50th, 75th and 
95th percentile. Pseu-pseudouridine; 1mA-1methyadenosine, 3mC-
3methylcytidine; X-xanthosine; A-adenosine; N4ac-N4acethylcyt-
idine; N2N2-N2N2dimethylguanosine; MTA-methythioadenosine; 
7mG-7methyladenosine; I-inosine; G-guanosine, 5mU-5methyluri-
dine; 6mA-6methyladenosine
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rates for MTA, is slightly lower, especially when cor-
rected by sex-dependent creatinine excretion rate.
We also checked the fit of the developed model with 
and without incorporation of case/control effect to evalu-
ate whether this covariate influences nucleosides/creatinine 
excretion rates. The DIC was found to be lower for model 
with case/control status in comparison to the model with-
out this covariate (ΔDIC = 31), which indicates improve-
ment of model accuracy.
3.3  Probability of cancer development
The validation set was used to evaluate the model perfor-
mance by calculating the probability of cancer for individu-
als with known nucleosides and creatinine concentration 
ratios, age and sex based on the model developed using the 
training set.
The accuracy of classification between patients and 
healthy individuals was summarized by area under the 
ROC, accuracy, sensitivity and specificity. The individual 
a posteriori prediction of disease occurrence along with 
5th and 95th percentiles expressed via area under the ROC 
was 0.57 (0.5–0.67) with sensitivity and specificity of 0.59 
(0.42–0.76) and 0.57 (0.45–0.7), respectively suggesting 
limited usefulness of nucleosides in predicting patients’ 
health status in this population.
The area under the ROC defines the relationship 
between the true positive rate (TPR, in other words a prob-
ability that a patient has a positive test result) and the false 
positive rate (FPR, a probability that a healthy individuals 
has a positive test result) from a binary response across 
all possible threshold values. The area under the ROC 
describes the probability that the outcome for a randomly 
drawn individuals from “diseased” group is higher than for 
a randomly drawn individuals from “healthy” group (Hos-
sain et al. 2015).
We therefore conclude, that predictive performance of 
nucleosides and creatinine concentration modelled in a 
function of age and sex, characterized by a posteriori area 
under the ROC is far from being acceptable in terms of 
candidate disease indicators.
To evaluate how this conclusion is reflected in an indi-
vidual person, we plotted the individual probability of 
cancer occurrence for randomly selected individuals from 
the validation set (Fig.  4). Based on that, we could make 
a rationale decision whether knowledge on nucleosides/
creatinine excretion rate adds any information to the prior 
probability of cancer for an individual person. The concept 
of establishing an individual probability of disease occur-
rence lies within the foundation of decision theory and 
has long been recognized in neuroscience and cognitive 
research (Körding 2007). In this work, using Bayesian sta-
tistics within a decision framework, a priori we assumed 
equal probability of cancer occurrence (0–1) and no knowl-
edge on health status of a patient or uncertainty associated 
with it. Following Bayesian concept, after seeing the data 
our probability for a particular patient is updated (posterior 
probability). The mean values of posterior distribution rep-
resent the most likely decision on the probability of cancer 
assuming the model and the available data. However, at this 
point it should be noted that prediction made for an individ-
ual patient can only be probabilistic due to uncertainty of a 
decision. In our opinion, the concept of using Bayesian sta-
tistics within a multilevel PK-driven modeling framework 
can be used in a decision framework and may have a practi-
cal usefulness in metabolomics regarding e.g. most benefi-
cial choices made by physician for an individual patient in 
terms of diagnosis and treatment (Hozo et al. 2015).
3.4  Biological inference on the effect 
of methylthioadenosine (MTA)
The effect for MTA observed in the model assuming 
informative prior on age and sex and normally-distributed 
regularizing prior on case/control effect, is evident. Such 
increase in MTA concentration may not be significant from 
clinical viewpoint, however its physiological role deserves 
attention and has already been addressed in the literature. 
Therefore, we further evaluated the relationship between 
MTA and the remaining nucleosides, assessing the pres-
ence of linear relationship between them through the 
observed estimates of variance–covariance Λ. The MTA 
exhibited the lowest correlation coefficient in relation to the 
remaining nucleosides which may suggest different meta-
bolic pathway for the remaining 12 nucleosides (Fig. 5).
MTA (5′-deoxy-5′-methylthioadenosine) is produced 
from S-(5′-deoxy-5′-adenosyl)-L-methionie during syn-
thesis of polyamines, spermidine and spermine. MTA is a 
principal substrate for the methylthioadenosine phosphory-
lase (MTAP) enzyme, which claves the MTA into adenine 
and methylthioribose-1-phosphate (Nobori et  al. 1996). 
Adenine is then salvaged to form AMP by the action of 
adenine phosphoribosyltransferase (Karikari et  al. 2005), 
and this is the only known source of free cellular adenine. 
MTA has been shown to affect the expression of a variety 
of transcription factors and genes involved in growth and 
apoptosis (Andreu-Pérez et al. 2010).
The MTAP plays an important role in adenine and meth-
ylthio- moieties of MTA recycling back to the metabolites 
from which S-adenosyl-L-methionine is formed – ATP and 
methionine. All normal mammalian tissues contain MTAP 
which maintains cellular MTA at a very low level. Since 
cancer cells are commonly MTAP-deficient, MTA is not 
metabolized but accumulates in cells and /or is excreted 
(Stevens et al. 2008).
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The mechanism behind MTAP deficiency lies in fre-
quent homogenous co-deletion of MTAP gene with the 
CDKN2A gene, which is responsible for encoding p16 
and p14ARF which are tumor suppressor proteins found 
in the chromosome 9p21 region. Lack of MTAP activity 
has been reported in approximately 40% of non-small cell 
lung, pancreatic, and biliary tract cancer, 70% of meso-
thelioma and glioblastoma, 35% of osteosarcoma, soft-
tissue sarcoma, and T-cell acute lymphoblastic leukemia 
(Lubin et al. 2009). Molecular studies using hepatocellu-
lar carcinoma cells (HCC) demonstrated down-regulation 
of MTAP expression in human HCC cell lines and tissues 
as compared to primary human hepatocytes and non-
tumorous tissue. LC–ESI–MS/MS revealed significantly 
higher intracellular and secreted MTA level as compared 
to non-tumorous liver tissue. Moreover in human HCC 
tissue, MTAP expression correlated inversely with MTA 
level. The MTAP down-regulation in HCC was proposed 
to be correlated with tumor staging and grading suggest-
ing MTA as potential biomarker for tumor progression. 
However, still there is little information on the molecular 
mechanisms of how the reduction of MTAP expression 
and increased MTA levels affect cancer (Kirovski et  al. 
2011).
Biological background behind the increased excretion 
of modified and unmodified nucleosides is elusive. How-
ever, RNA turnover is known to be responsible for release 
of nucleosides thanks to the activity of ribonucleases and 
phosphatases. The same enzymes are capable to recycle 
ribonucleosides, such as cytidine, guanosine, uridine or 
adenosine for RNA rebuilding process in the commonly 
known salvage pathway. It’s been reported that modified 
nucleosides participate in tRNA discrimination, translation 
fidelity via codon–anticodon interaction, maintenance of 
Fig. 4  Correlation matrix demonstrating the degree of linear relationship beetween nucleosides. The variables are ordered according to the 
value of Pearson correlation coefficient. The lighter the color the lesser coefficient value between two variables
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reading frame, tRNA stability and quality control (Hopper 
2013).
Moreover reduction, substitution or isomerization, to 
which RNA is subjected, produce modified nucleosides 
which cannot be recycled to rebuild RNA due to the lack of 
specific phosphorylases. However, these modifications are 
important in order to improve integrity, biological activity 
and efficiency of RNA at a biochemical level. Thus, any 
pathophysiological state or metabolic imbalance which 
affects RNA turnover or breakdown is assumed to influence 
the levels of excreted nucleosides (Hsu et al. 2013).
4  Conclusions
The feature which distinguishes multilevel models from 
classical regression (used e.g. in metabolomics), relates to 
modeling the variation. Within this concept, we consider 
Fig. 5  Individual distribution of prior and posterior probability of 
cancer estimated based on 13 nucleosides/creatinine excretion rates 
for 12 randomly selected individuals from the validation set. Red dot-
ted line represents the prior assumed, histograms denote posterior 
probability distribution. Vertical blue line denotes the mean of poste-
rior probability of cancer
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a multilevel model to be a regression model in which the 
parameters are provided a probability model. Accordingly, 
this second-level model has its own parameters (known 
as model hyperparameters) which are also estimated from 
data (Gelman et  al. 2007). This idea of Bayesian multi-
level modeling is based on conceptual knowledge and has 
already been applied in the field of natural and political sci-
ence (McElreath 2014) and pharmacokinetics (Wakefield 
1996; Wiczling 2016).
In this study we introduced the concept of Bayesian mul-
tilevel modeling to large-sample, unbalanced, sex and age-
unadjusted targeted metabolomics data. Within this meth-
odology, we provided physiologically-based PK model 
describing nucleoside-specific biology behind the urogeni-
tal tract cancer, related to covariates (age, sex, case/control 
status) and between-subject variability. The proposed meth-
odology offers a new possibility for clinical decision mak-
ing due to establishing an individual probability of disease 
occurrence. In this context, we think that Bayesian statistics 
within a decision framework can influence the field of bio-
marker studies in various aspects not only limited to metab-
olomics. Within biological context, we conclude limited 
usefulness of nucleosides to predict urogenital tract cancer 
in our population, however still information provided by 
nucleosides, should not be completely ignored. Especially 
the evidence of MTA association with cancer requires fur-
ther studies to elucidate whether this effect is really caused 
by cancer or whether it is another factor associated with it.
To sum up, we conclude that dealing with both, large- 
and small-sample, unbalanced and unadjusted data sets 
forces the use of methods other than those based on clas-
sical hypothesis-significance-testing, which by defini-
tion were designed to investigate large and stable effects 
(however the methodology proposed can also be applied to 
balanced and adjusted datasets). In non-targeted metabo-
lomics, measuring thousands of signals in a sample make 
the investigated effects highly context dependent, noisy 
with plenty of missing data points. In such case, multilevel 
Bayesian approach allows modeling concentrations below 
and above detection limit without the need to discard those 
data points prior modeling. Within the context of big data 
modeling, regularizing prior imposed on model parameters 
shrinks them toward zero simultaneously reducing their 
variance which further results in model overfitting reduc-
tion. The methodology proposed also allows to account 
for other sources of variability than between-subject and 
intra-subject variability, e.g. between-occasion, between-
laboratory, between different analytical techniques. Simul-
taneously, we can estimate uncertainty around model 
parameters and predictions and reduce multiple testing 
problem.
Therefore, new methodologies for the analysis of metab-
olomics data should be adopted from other disciplines in 
order to make a proper inference from the data and provide 
a rational decisions in further clinical applications.
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